# Eli Lilly Price Target Boost

> Berenberg upgrades Eli Lilly to Buy with 20% upside potential.
- Title: Eli Lilly Price Target Boost · Yahoo Finance | Shortify
- Summary: Berenberg upgrades Eli Lilly to Buy with 20% upside potential. Berenberg raised Eli Lilly's price target to $1,400 from $1,220, predicting 20% upside based…
- Keywords: berenberg, eli lilly, zepbound, mounjaro, foundayo, obesity treatment, glp-1 drug, medicare bridge, price target, stock analysis, business, finance
- Source: Yahoo Finance — https://finance.yahoo.com/markets/stocks/articles/eli-lilly-lly-gets-big-155107945.html
- Published: 2026-09-17T15:51:07+00:00
- Read time: 1 min
- Topics: berenberg, eli lilly, zepbound, mounjaro, foundayo, obesity treatment, glp-1 drug, medicare bridge, price target, stock analysis, business, finance
## Berenberg Upgrades Eli Lilly
Berenberg upgraded Eli Lilly from Hold to Buy and raised its price target from $1,220 to $1,400 on September 15, 2026.
## Obesity Treatment Growth
Eli Lilly's Zepbound and Mounjaro lead obesity and diabetes treatments, with potential for 25% stock upside from Foundayo's diabetes approval.
## Pipeline Investments
Eli Lilly committed $60 billion across 25+ business development deals this year, with multibillion-dollar sales potential in new pipeline assets.
## Pricing Challenges
Eli Lilly's US price declined 3% year-over-year, with a 9% decline excluding rebates and discounts, showing pricing pressure.
## Foundayo Launch
Foundayo has a slow US launch but is under regulatory review in 40+ countries, with expected approvals later this year.
## Investor Sentiment
Analysts expect Eli Lilly to exceed 2026 guidance with a median price target of $1,392.50, implying 22.38% upside potential.
## Key takeaway

Berenberg raised Eli Lilly's price target to $1,400 from $1,220, predicting 20% upside based on obesity treatment growth and pipeline investments.